AI Article Synopsis
- Fatigue is a major issue for Multiple Sclerosis (MS) patients and affects their quality of life; the study focused on how Fingolimod (Fg), an oral MS treatment, impacts fatigue in the first 6 months.
- A prospective study measured fatigue using the Modified Fatigue Impact Scale and other assessments, with 54 participants completing the study.
- Results showed no significant change in fatigue levels after 6 months of Fg treatment, although patients with higher fatigue levels had worse disability scores but similar fatigue evolution compared to lower fatigue patients.
Article Abstract
Background: Fatigue is one of the most disabling symptoms in Multiple Sclerosis (MS) patients and is associated with a low quality of life. Fingolimod (Fg), a sphingosine 1-phosphate receptor modulator, is the first oral MS disease modifying treatment. Little is known about its effect on fatigue. To assess the impact of Fg on fatigue within the first 6 months of treatment in MS patients, we conducted a prospective, open label study, in real life setting.
Methods: Change of Modified Fatigue Impact Scale (MFIS) between Fg treatment start and at 6 months was used as a first outcome. Secondary outcomes were changes of MFIS subscales, Fatigue severity scale (FSS) and Visual Analogic Scale of Fatigue (VAS-F) scores, RESULTS: 54 completed the study at M6. No significant change was noted in global MFIS (and neither in sub analysis of MFIS), FSS or VAS-F at M6. Patients with high level of fatigue (MFIS or ≥38) had a higher EDSS score than patients with lower level of fatigue (MFIS <38), (mean 3.3, [SD 1.6] versus 1.6 [SD1.1], p=0.0002) but showed no significant difference in MFIS evolution at M6. There was no significant statistical difference in fatigue parameters evolution at M6 within patients Nz+ or Nz-.
Conclusion: There is no significant impact of Fg on fatigue after 6 months of treatment.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1016/j.msard.2017.03.006 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Effects of analgesic delivery on pelvic floor function of primiparous women.
Afr J Reprod Health
November 2024
Department of Obstetrics and Gynecology, Binhai County People's Hospital, The Affiliated Hospital of Kangda College of Nanjing Medical University, Yancheng 224500, Jiangsu, China.
This was an original article, and the objective of this study was to clarify the short-term effects of analgesic delivery on the pelvic floor function of primiparous women. Three hundred primiparas who delivered vaginally in The Affiliated Hospital of Kangda College of Nanjing Medical University from January 2022 to July 2022 were enrolled, and were divided into control and intervention groups. The control accepted traditional delivery without special analgesic intervention, while the intervention group accepted intraspinal block analgesia at the time of delivery.
View Article and Find Full Text PDFInterface-Engineered Manufacturing of Gradient Wood with Heterogeneous Structure for Lightweight and Sustainable Structural Materials.
Nano Lett
January 2025
Co-Innovation Center of Efficient Processing and Utilization of Forest Resources, Nanjing Forestry University, Nanjing 210037, China.
Developing sustainable structural materials to replace traditional carbon-intensive structural materials fundamentally reshapes the concept of circular development. Herein, we propose an interface engineering strategy that utilizes water as a liquid medium to replace the residual air within natural wood. This approach minimizes the absorption of water-based softening agents by microcapillary channels of wood, enabling the controlled softening of the cell walls.
View Article and Find Full Text PDFTreatment Advances in Tumor-Induced Osteomalacia.
Calcif Tissue Int
January 2025
National Institute of Dental and Craniofacial Research, NIH, Bethesda, MD, 20892, USA.
Tumor-induced osteomalacia (TIO) is a rare paraneoplastic syndrome caused by hypersecretion of fibroblast growth factor 23 (FGF23) by typically benign phosphaturic mesenchymal tumors (PMTs). FGF23 excess causes chronic hypophosphatemia through renal phosphate losses and decreased production of 1,25-dihydroxy-vitamin-D. TIO presents with symptoms of chronic hypophosphatemia including fatigue, bone pain, weakness, and fractures.
View Article and Find Full Text PDFCytokine dynamics and quality of life: unraveling the impact of cell-free and concentrated ascites reinfusion therapy in ovarian cancer patients.
Int J Clin Oncol
January 2025
Department of Obstetrics and Gynecology, Iwate Medical University School of Medicine, 2-1-1, Idaidori, Yahaba, Iwate, 028-3695, Japan.
Background: The quality of life (QOL) of ovarian cancer patients is often impaired by refractory ascites. Cell-free and concentrated ascites reinfusion therapy (CART) is a palliative treatment for refractory ascites, but adverse events, such as fever, are problematic. Several cytokines have been suggested to be responsible for the adverse events, but they have not been investigated in detail.
View Article and Find Full Text PDFHierarchically aligned heterogeneous core-sheath hydrogels.
Nat Commun
January 2025
Institute of Innovative Materials, Department of Chemistry, College of Science, Southern University of Science and Technology, Shenzhen, China.
Natural materials with highly oriented heterogeneous structures are often lightweight but strong, stiff but tough and durable. Such an integration of diverse incompatible mechanical properties is highly desired for man-made materials, especially weak hydrogels which are lack of high-precision structural design. Herein, we demonstrate the fabrication of hierarchically aligned heterogeneous hydrogels consisting of a compactly crosslinked sheath and an aligned porous core with alignments of nanofibrils at multi-scales by a sequential self-assembly assisted salting out method.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!